期刊文献+

甾体5α-还原酶抑制剂的高效液相色谱法体外筛选模型 被引量:4

Screen steroid 5 alpha-reductase inhibitors in vitro by high performance liquid chromatography
原文传递
导出
摘要 报道了一种用高效液相色谱法(HPLC)筛选甾体5α-还原酶抑制剂的体外模型.将甾体5α-还原酶液、睾酮溶液、辅酶(NADPH)与5α-还原酶抑制剂(非那甾胺和爱普列特)在37℃下反应30 min,反应终止后,通过HPLC测定反应前后底物睾酮量的变化来分析酶的活性,进而由酶活性的降低来判断抑制剂对5α-还原酶的抑制作用.将实验数据按Lineweaver-Burk倒数作图,求得甾体类抑制非那甾胺抑制常数Ki=4.32±0.38μmol/L,爱普列特抑制常数Ki=1.14±0.23μmol/L.实验所得的数据和图形均说明了本实验所采用的高效液相色谱法作为一种甾体5α-还原酶抑制剂体外筛选模型是简便可行的. An in vitro method to screen steroid 5 alpha-reductase inhibitors by high performance liquid chromatography was reported. Steroid 5 alpha-reductase, series concentration of testosterone and Finasteride (or Epristeride) were incubated at 37℃ for 30 rain. Then the samples were analyzed by HPLC with C18 column. The descending rate of the concentration of testosterone showed the activity of the enzymatic. And inhibition constant (Ki) of the steroid 5α-reductatse inhibitors could be calculated according to the Lineweaver-Burk plots. The Ki values of Finasteride and Epristeride were Ki=4.32±3.8 μmol/L and 1. 14±0.23 μmol/L, respectively. The results indicated that the method is rapid and efficient to screen steroid 5 alpha-reductase inhibitors in vitro.
出处 《福州大学学报(自然科学版)》 CAS CSCD 北大核心 2005年第5期661-664,678,共5页 Journal of Fuzhou University(Natural Science Edition)
关键词 高效液相色谱 甾体5α-还原酶 非那甾胺 爱普列特 high performance liquid chromatography (HPLC) steroid 5α-reductatse inhibitors Finasteride Epristeride
  • 相关文献

参考文献9

  • 1Kortt Michael A, Bootman J Lyle. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review[ J]. Clinical Therapeutics, 1996, 18(6): 1 227 - 1 241.
  • 2蒋晟,廖清江.甾体5α-还原酶抑制剂的研究进展[J].中国新药杂志,2000,9(7):438-442. 被引量:8
  • 3Eli Lilly, Company. LY 191701: type 1 steroid 5α- reductase inhibitor treatment of androgenic alopecia[J]. Drugs Fut, 1995, 20(2): 144 - 147.
  • 4孙祖越,吴建辉,屠曾宏,朱焰,钟恩宏.一个简捷的甾体5α-还原酶抑制剂体外筛选模型[J].上海实验动物科学,2002,22(4):204-208. 被引量:11
  • 5孙祖越,郑维君,王晓麟,屠曾宏.甾体5α-还原酶活性的新测定方法[J].中华内分泌代谢杂志,1998,14(3):206-207. 被引量:6
  • 6崔毓桂,张桂元.正常成年男性5a-还原酶活性的测定[J].生殖医学杂志,1995,4(1):11-15. 被引量:9
  • 7Imperato - McGinley J, Sanchez R S, Spencer J R, et al. Comparison of the effects of the 5 alpha - reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose - response studies[ J ]. Endocrinology, 1992, 131 (3) :1149-1156.
  • 8E di sale, D Gidici L Biagini, C Cominato, et al. Effects of 5α - reductase inhibitors on intraprostatic androgens in the rat[J]. J Steroid Biochem Molec Biol, 1995, 53(1 - 6): 381 - 385.
  • 9George G, Guilbault. Handbook of enzymatic methods of analysis [ M ]. New York: Marcel Dekker Inc, 1976.99.

二级参考文献20

  • 1吴建辉,朱焰,孙祖越.治疗前列腺增生的国家一类新药——爱普列特[J].药学进展,2002,26(1):55-57. 被引量:19
  • 2崔毓桂,张桂元.正常成年男性5a-还原酶活性的测定[J].生殖医学杂志,1995,4(1):11-15. 被引量:9
  • 3崔毓桂.类固醇5α-还原酶与5α-还原酶缺乏症[J].国外医学(内分泌学分册),1995,15(1):4-7. 被引量:5
  • 4孙祖越,屠曾宏.治疗良性前列腺增生新药爱普列特的国外研究概况[J].药学进展,1995,19(4):211-215. 被引量:8
  • 5张昌颖.中国医学百科全书--生物化学[M].上海:上海科学技术出版社,1989.192-193.
  • 6 Levy MA, Brandt M, Greway AT. Mechanistic studies with solubilized rat liversteroid 5α-reductase: eluciodation of the kinetic mechanism[J].Biochemistry,1990,29(11)∶2808 [3] Levy MA, Brandt M, Richard H,et al. Inhibition of rat liver steroid 5α-reductaseby 3-androstene-3-carboxylic acids: Mechanism of enzyme inhibitor interaction[J].Biochemistry,1990,29(11)∶2814~2815
  • 7 Kenny B, Miller AM, Williamson JR,et al. Pharmacological options in thetreatment of benign prostatic hyperplasia[J].J Med Chem,1997,40(9)∶1293~1315
  • 8 Baskshi RK, Patel GF, Rasumusson GH, et al.4,7β-dimethyl-4-azachlolestan-3-one(MK-386)and related 4-azasteroids as selective inhibitors of human type Ⅰ5α-reductase [J].JMed Chem, 1994,37(23)∶3871~3874
  • 9 Salle ED, Pazeri A. Testosterone 5α-reductase inhibitor[J].DrugsFut,1993,18(5)∶436~439
  • 10 Finasteride[J].Annu Drug Data Rep,1992,14(10)∶996~999

共引文献27

同被引文献38

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部